{"id":62790,"date":"2026-03-16T01:07:38","date_gmt":"2026-03-16T00:07:38","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\/"},"modified":"2026-03-16T01:07:38","modified_gmt":"2026-03-16T00:07:38","slug":"samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\/","title":{"rendered":"Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<b><i>Samsung Bioepis to receive exclusive license to develop and commercialize two novel assets including long-acting semaglutide using G2GBIO\u2019s proprietary microsphere technology<\/i><\/b><\/li>\n<li>\n<b><i>Epis NexLab, a sister company to Samsung Bioepis under Samsung Epis Holdings, also signs the agreement to collaborate in the development of the long-acting microsphere drug delivery platform<\/i><\/b><\/li>\n<\/ul>\n<p>INCHEON, Korea&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/Biosimilar?src=hash\" target=\"_blank\">#Biosimilar<\/a>&#8211;Samsung Bioepis Co., Ltd. and Epis NexLab Co., Ltd., a sister company to Samsung Bioepis under Samsung Epis Holdings (KRX: 0126Z0), today announced a research collaboration and license agreement with G2GBIO, a company specializing in the development of sustained-release formulations, to develop novel assets based on G2GBIO\u2019s proprietary microsphere technology.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20260316253695\/en\/608568\/5\/Samsung_Bioepis_Logo_2.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260316253695\/en\/608568\/22\/Samsung_Bioepis_Logo_2.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20260316253695\/en\/608568\/5\/Samsung_Bioepis_Logo_2.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260316253695\/en\/608568\/21\/Samsung_Bioepis_Logo_2.jpg\"><\/a><\/p>\n<p>\nUnder the agreement, Samsung Bioepis will be given a full license right for the novel long-acting semaglutide asset, and an option to license another asset from G2GBIO. In addition, Samsung Bioepis will be given the first negotiation rights for the three other novel assets to be determined. Epis NexLab will be responsible for the co-development of the long-acting microsphere drug delivery platform using G2GBIO\u2019s proprietary technology. The details of the financial terms remain confidential.<\/p>\n<p>\n\u201cThis agreement represents an important step in expanding our drug delivery capabilities and pipeline,\u201d said Kyung-Ah Kim, President and Chief Executive Officer, at Samsung Bioepis. \u201cBy leveraging G2GBIO\u2019s proprietary microsphere technology and collaborating with Epis NexLab, we look forward to the development of innovative therapies and deliver meaningful treatment options to patients.\u201d<\/p>\n<p>\n<b><span class=\"bwuline\">About Samsung Bioepis Co., Ltd.<\/span><\/b><\/p>\n<p>\nEstablished in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world&#8217;s leading biopharmaceutical company. As a wholly owned subsidiary of Samsung Epis Holdings, Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, endocrinology. For more information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.samsungbioepis.com&amp;esheet=54446556&amp;newsitemid=20260316253695&amp;lan=en-US&amp;anchor=www.samsungbioepis.com&amp;index=1&amp;md5=17648f7f27786774de64e18b21b06984\" rel=\"nofollow\" shape=\"rect\">www.samsungbioepis.com<\/a> and follow us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsamsungbioepis%2F&amp;esheet=54446556&amp;newsitemid=20260316253695&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=2&amp;md5=dc5994428020f0142f98dac4dc786b99\" rel=\"nofollow\" shape=\"rect\">LinkedIn<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FSamsungBioepis%2F&amp;esheet=54446556&amp;newsitemid=20260316253695&amp;lan=en-US&amp;anchor=X&amp;index=3&amp;md5=3e61984eb4742ec96c4858fc43c7a3de\" rel=\"nofollow\" shape=\"rect\">X<\/a>.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b><span class=\"bwuline\">Media Contact<\/span><\/b><br \/>Yoon Kim, <a target=\"_blank\" href=\"&#109;&#x61;&#x69;&#108;&#x74;&#x6f;:&#x79;&#x6f;o&#110;&#x31;&#46;&#107;&#x69;m&#64;&#x73;a&#109;&#x73;u&#110;&#x67;&#x2e;&#99;&#x6f;&#x6d;\" rel=\"nofollow\" shape=\"rect\">&#x79;&#111;&#x6f;&#110;1&#x2e;&#107;i&#x6d;&#64;&#x73;&#x61;m&#x73;&#117;n&#x67;&#46;&#x63;&#x6f;m<\/a><br \/>Anna Nayun Kim, <a target=\"_blank\" href=\"&#x6d;a&#x69;&#108;&#x74;&#111;&#x3a;&#x6e;a&#x79;&#117;&#x6e;&#56;&#x36;&#46;k&#x69;&#109;&#x40;&#115;&#x61;&#109;s&#x75;&#110;&#x67;&#46;&#x63;&#111;m\" rel=\"nofollow\" shape=\"rect\">n&#97;&#121;&#x75;&#x6e;&#x38;&#x36;&#46;&#107;&#105;&#109;&#x40;&#x73;&#x61;ms&#117;&#110;&#x67;&#x2e;&#x63;om<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Samsung Bioepis to receive exclusive license to develop and commercialize two novel assets including long-acting semaglutide using G2GBIO\u2019s proprietary microsphere technology Epis NexLab, a sister company to Samsung Bioepis under Samsung Epis Holdings, also signs the agreement to collaborate in the development of the long-acting microsphere drug delivery platform INCHEON, Korea&#8211;(BUSINESS WIRE)&#8211;#Biosimilar&#8211;Samsung Bioepis Co., Ltd. &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62790","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Samsung Bioepis to receive exclusive license to develop and commercialize two novel assets including long-acting semaglutide using G2GBIO\u2019s proprietary microsphere technology Epis NexLab, a sister company to Samsung Bioepis under Samsung Epis Holdings, also signs the agreement to collaborate in the development of the long-acting microsphere drug delivery platform INCHEON, Korea&#8211;(BUSINESS WIRE)&#8211;#Biosimilar&#8211;Samsung Bioepis Co., Ltd. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-16T00:07:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260316253695\/en\/608568\/22\/Samsung_Bioepis_Logo_2.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide\",\"datePublished\":\"2026-03-16T00:07:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\\\/\"},\"wordCount\":370,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260316253695\\\/en\\\/608568\\\/22\\\/Samsung_Bioepis_Logo_2.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\\\/\",\"name\":\"Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260316253695\\\/en\\\/608568\\\/22\\\/Samsung_Bioepis_Logo_2.jpg\",\"datePublished\":\"2026-03-16T00:07:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260316253695\\\/en\\\/608568\\\/22\\\/Samsung_Bioepis_Logo_2.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260316253695\\\/en\\\/608568\\\/22\\\/Samsung_Bioepis_Logo_2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\/","og_locale":"en_US","og_type":"article","og_title":"Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide - Pharma Trend","og_description":"Samsung Bioepis to receive exclusive license to develop and commercialize two novel assets including long-acting semaglutide using G2GBIO\u2019s proprietary microsphere technology Epis NexLab, a sister company to Samsung Bioepis under Samsung Epis Holdings, also signs the agreement to collaborate in the development of the long-acting microsphere drug delivery platform INCHEON, Korea&#8211;(BUSINESS WIRE)&#8211;#Biosimilar&#8211;Samsung Bioepis Co., Ltd. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\/","og_site_name":"Pharma Trend","article_published_time":"2026-03-16T00:07:38+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260316253695\/en\/608568\/22\/Samsung_Bioepis_Logo_2.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide","datePublished":"2026-03-16T00:07:38+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\/"},"wordCount":370,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260316253695\/en\/608568\/22\/Samsung_Bioepis_Logo_2.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\/","url":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\/","name":"Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260316253695\/en\/608568\/22\/Samsung_Bioepis_Logo_2.jpg","datePublished":"2026-03-16T00:07:38+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260316253695\/en\/608568\/22\/Samsung_Bioepis_Logo_2.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260316253695\/en\/608568\/22\/Samsung_Bioepis_Logo_2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62790"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62790\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62790"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62790"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}